Statin use reduces cataract & AMD risk

Article

Statins may have protective effects on the development of both cataract and age-related macular degeneration (AMD), according to a report published in the April issue of the American Journal of Ophthalmology.

Statins may have protective effects on the development of both cataract and age-related macular degeneration (AMD), according to a report published in the April issue of the American Journal of Ophthalmology.

Jennifer Tan and colleagues from the Centre for Vision Research, University of Sydney, Australia examined the relationship between statin use and long-term incidence of cataract and AMD using participants from the Blue Mountains Eye Study.

A total of 2,335 participants were re-examined at five years and 1,952 at 10 years. After controlling for age and gender, compared with non-users, statin users had a reduced risk of developing indistinct soft drusen, the principal late AMD precursor lesion (hazard ratio, 0.33; 95% confidence interval, 0.13 to 0.84).

The authors also discovered that statin use can reduce the risk of cataract development by up to 50%.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.